Scientists have demonstrated that a carefully designed vaccine can trigger the production of broadly neutralizing antibodies (bnAbs) against HIV in monkeys, a long-sought goal in the fight against the virus. The findings, published in Nature by researchers from Scripps Research and the International AIDS Vaccine Initiative, mark a significant step toward a preventive vaccine for humans.
The study tackles HIV’s notorious ability to mutate rapidly, which has thwarted traditional vaccine approaches. By using a series of immunogens that guide the immune system through intermediate steps, the researchers were able to elicit bnAbs that target conserved regions of the virus’s surface.
All six vaccinated monkeys produced detectable bnAbs, with some achieving neutralization activity against multiple HIV strains. The response was modest in potency compared to natural infection but lasted for months after the final booster. No serious adverse effects were reported.
The ultimate goal is to translate this into a multi-dose regimen for humans, though challenges remain. The price of such vaccines will also be a determining factor for global access, particularly in sub-Saharan Africa where the HIV burden is highest.